Boehringer Ingelheim USA Corporation

The weight-loss treatment market is expected to see 16 new drugs by 2029, expanding the market to $200 billion by 2031, driven by interest sparked by Novo Nordisk and Eli Lilly. Amgen and Pfizer are among companies testing their drug candidates, which could lower prices amid criticism over high costs.

PhoreMost Ltd secured an additional €10.8m to advance oncology and inflammation degrader programmes and its AI-supported GlueSEEKER™ platform for novel molecular glue degraders.

OSE Immunotherapeutics launches Artemia Phase 3 trial for Tedopi® in second-line NSCLC, targeting HLA-A2+ patients with secondary resistance to ICI, aiming for regulatory registration in Europe and North America.

Boehringer Ingelheim's zongertinib showed significant objective response rate (ORR) in advanced NSCLC patients with HER2 mutations, with 66.7% ORR and 94% tumor shrinkage. The treatment was well tolerated, with no deaths reported and common AEs being rash and diarrhea.

Walgreens launched its clinical trial business in June 2022, leveraging its national retail pharmacy network for patient recruitment, trial conduct, and real-world evidence services. The company has expanded its services, focusing on insights-driven patient recruitment, trial conduct, and real-world evidence informatics. Walgreens has successfully enrolled diverse patient populations in various trials, addressing historical underrepresentation in research. The company aims to continue its role in decentralizing clinical research, making trials more accessible and representative.

Boehringer Ingelheim reported positive outcomes from the Beamion LUNG-1 trial, assessing zongertinib for treating NSCLC with HER2 mutations. The trial met its primary endpoint, showing a 66.7% objective response rate and a tolerable safety profile, with no treatment-related deaths.

The North America CMO and CDMO biotechnology market is robust, segmented by applications like oncology, cardiology, immunology, neurology, and metabolic diseases. Key manufacturers include Patheon, Catalent, Samsung Biologics, and Lonza. The market is driven by technological advancements and growing demand for automation, with a promising future for innovation and growth.